EA201890893A1 - Способы лечения повреждений или состояний, относящихся к отеку цнс - Google Patents
Способы лечения повреждений или состояний, относящихся к отеку цнсInfo
- Publication number
- EA201890893A1 EA201890893A1 EA201890893A EA201890893A EA201890893A1 EA 201890893 A1 EA201890893 A1 EA 201890893A1 EA 201890893 A EA201890893 A EA 201890893A EA 201890893 A EA201890893 A EA 201890893A EA 201890893 A1 EA201890893 A1 EA 201890893A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cns
- treatment
- damage
- reducing
- conditions
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 206010030113 Oedema Diseases 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000012544 monitoring process Methods 0.000 abstract 2
- 230000000926 neurological effect Effects 0.000 abstract 2
- 206010048962 Brain oedema Diseases 0.000 abstract 1
- 108091006146 Channels Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 208000006752 brain edema Diseases 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 229940125400 channel inhibitor Drugs 0.000 abstract 1
- 230000006866 deterioration Effects 0.000 abstract 1
- 238000006073 displacement reaction Methods 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000008961 swelling Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238461P | 2015-10-07 | 2015-10-07 | |
| PCT/US2016/055988 WO2017062765A1 (en) | 2015-10-07 | 2016-10-07 | Methods of treating injuries or conditions related to cns edema |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201890893A1 true EA201890893A1 (ru) | 2018-09-28 |
Family
ID=58488580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201890893A EA201890893A1 (ru) | 2015-10-07 | 2016-10-07 | Способы лечения повреждений или состояний, относящихся к отеку цнс |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20180280325A1 (enExample) |
| EP (1) | EP3359162B1 (enExample) |
| JP (4) | JP7349786B2 (enExample) |
| KR (2) | KR102681027B1 (enExample) |
| CN (2) | CN108348534A (enExample) |
| AU (3) | AU2016335767B2 (enExample) |
| BR (1) | BR112018006925A2 (enExample) |
| CA (1) | CA3001321A1 (enExample) |
| EA (1) | EA201890893A1 (enExample) |
| ES (1) | ES2940669T3 (enExample) |
| HK (1) | HK1257542A1 (enExample) |
| IL (1) | IL258509B2 (enExample) |
| MA (1) | MA45574A (enExample) |
| MX (1) | MX392466B (enExample) |
| WO (1) | WO2017062765A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2872012C (en) | 2012-05-08 | 2017-06-20 | Aeromics, Llc | New methods |
| CN106163506A (zh) | 2013-11-06 | 2016-11-23 | 埃罗米克斯公司 | 新配方 |
| MA45574A (fr) * | 2015-10-07 | 2019-05-15 | Biogen Chesapeake Llc | Procédés de traitement de lésions ou de pathologies liées à un dème du snc |
| WO2020041905A1 (en) * | 2018-08-31 | 2020-03-05 | The University Of British Columbia | Methods for identifying compounds suitable for treatment of central nervous system trauma and uses of those compounds |
| EP3962466A4 (en) * | 2019-05-02 | 2023-01-25 | Biogen Chesapeake LLC | METHODS OF TREATMENT OF PERSONS WITH CONtusions Of The Central Nervous System |
| JP7781851B2 (ja) * | 2020-07-17 | 2025-12-08 | 上海森輝医薬有限公司 | スルホニル尿素誘導体及びその医薬用途 |
| US12251388B1 (en) * | 2024-05-09 | 2025-03-18 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
| WO2025212154A1 (en) * | 2024-04-05 | 2025-10-09 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
| WO2025212189A1 (en) * | 2024-04-05 | 2025-10-09 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema using a sur1-trpm4 channel inhibitor |
| WO2025212155A1 (en) * | 2024-04-05 | 2025-10-09 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke with large vessel occlusion using a sur1-trpm4 channel inhibitor |
| US12251389B1 (en) | 2024-04-22 | 2025-03-18 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5856360A (en) | 1996-05-03 | 1999-01-05 | Children's Hospital Medical Center | Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock |
| JP4485806B2 (ja) | 2002-03-20 | 2010-06-23 | ユニヴァーシティ オブ メリーランド，ボルチモア | 神経系細胞の非選択的陽イオンチャネルおよび脳腫脹を治療する方法 |
| US8980952B2 (en) * | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
| US20050246000A1 (en) * | 2004-05-03 | 2005-11-03 | Seacoast Technologies, Inc. | Cooled craniectomy |
| CA2691199C (en) | 2007-06-22 | 2017-09-12 | Marc J. Simard | Inhibitors of ncca-atp channels for therapy |
| PL2868315T3 (pl) * | 2007-12-04 | 2018-06-29 | Biogen Chesapeake Llc | Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty |
| JP6188021B2 (ja) * | 2010-07-19 | 2017-08-30 | バイオジェン チェサピーク エルエルシー | グリブリドおよび他の薬剤の静脈内投与方法 |
| MA45574A (fr) * | 2015-10-07 | 2019-05-15 | Biogen Chesapeake Llc | Procédés de traitement de lésions ou de pathologies liées à un dème du snc |
-
2016
- 2016-10-07 MA MA045574A patent/MA45574A/fr unknown
- 2016-10-07 KR KR1020187012950A patent/KR102681027B1/ko active Active
- 2016-10-07 CN CN201680066630.6A patent/CN108348534A/zh active Pending
- 2016-10-07 EP EP16854422.9A patent/EP3359162B1/en active Active
- 2016-10-07 US US15/763,932 patent/US20180280325A1/en not_active Abandoned
- 2016-10-07 BR BR112018006925A patent/BR112018006925A2/pt not_active Application Discontinuation
- 2016-10-07 ES ES16854422T patent/ES2940669T3/es active Active
- 2016-10-07 KR KR1020247021781A patent/KR20240105519A/ko not_active Ceased
- 2016-10-07 CA CA3001321A patent/CA3001321A1/en active Pending
- 2016-10-07 JP JP2018517841A patent/JP7349786B2/ja active Active
- 2016-10-07 AU AU2016335767A patent/AU2016335767B2/en active Active
- 2016-10-07 CN CN202211412393.8A patent/CN115737816A/zh active Pending
- 2016-10-07 EA EA201890893A patent/EA201890893A1/ru unknown
- 2016-10-07 HK HK18116503.6A patent/HK1257542A1/zh unknown
- 2016-10-07 MX MX2018004286A patent/MX392466B/es unknown
- 2016-10-07 IL IL258509A patent/IL258509B2/en unknown
- 2016-10-07 WO PCT/US2016/055988 patent/WO2017062765A1/en not_active Ceased
-
2021
- 2021-02-16 JP JP2021022562A patent/JP2021073317A/ja not_active Withdrawn
- 2021-09-29 US US17/488,591 patent/US11951085B2/en active Active
-
2022
- 2022-11-28 AU AU2022279369A patent/AU2022279369B2/en active Active
-
2023
- 2023-02-13 JP JP2023020327A patent/JP7592768B2/ja active Active
-
2024
- 2024-03-04 US US18/595,205 patent/US20240216309A1/en active Pending
- 2024-08-23 JP JP2024142687A patent/JP2024164167A/ja active Pending
- 2024-09-30 US US18/902,504 patent/US20250017880A1/en active Pending
-
2025
- 2025-04-14 AU AU2025202620A patent/AU2025202620A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201890893A1 (ru) | Способы лечения повреждений или состояний, относящихся к отеку цнс | |
| EA201890059A1 (ru) | Ингибиторы hpk1 и способы их применения | |
| ZA201907052B (en) | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | |
| EP4616902A3 (en) | Nerve stimulation for treating migraine and other headache conditions | |
| EA201991556A1 (ru) | Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции | |
| MX2020008906A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. | |
| EA201891539A1 (ru) | Соединения, ингибирующие металлоферменты | |
| EA201391019A1 (ru) | Соединения и способы для модуляции киназ, а также показания к их применению | |
| MX380901B (es) | Compuestos inhibidores de parg. | |
| MX2017009571A (es) | Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer. | |
| BR112017012402A2 (pt) | derivados de 2,4-dioxo-quinazolina-6-sulfonamida como inibidores de parg | |
| EA201390711A1 (ru) | Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения | |
| EA201690007A1 (ru) | Соединения, ингибирующие металлоферменты | |
| UA114090C2 (uk) | Сполуки, що інгібують металоферменти | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| EA201490052A1 (ru) | Соединения, ингибирующие металлоферменты | |
| EA201490038A1 (ru) | Соединения, ингибирующие металлоферменты | |
| JOP20120246B1 (ar) | مركبات و تركيبات كمثبطات كيناز c-Kit | |
| EA201291107A1 (ru) | Соединения, ингибирующие металлоферменты | |
| EA201491385A1 (ru) | Соединения, ингибирующие металлоферменты | |
| EA201491151A1 (ru) | Соединения, ингибирующие металлоферменты | |
| EA201492184A1 (ru) | Способы лечения метаболического синдрома путем модулирования белка теплового шока (hsp) 90-бета | |
| MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
| MY181808A (en) | Method for the treatment of fibrotic disease | |
| EA201791644A1 (ru) | Ингибиторы mir-92 и их применение |